INVESTOR WEBINAR:
Rakovina Therapeutics Announces Prioritizing
AI-Driven Drug Development
At Rakovina Therapeutics (TSX-V: RKV) we're on a mission to transform the landscape of cancer research and treatment. Watch this insightful webinar where we unveil how Rakovina Therapeutics is harnessing the power of AI to revolutionize cancer research.
TOPICS COVERED
- How we're leveraging AI to reduce research time and costs
- The impact of our innovations on cancer patients and the biotech industry
- Our recent recognition as one of the Top 10 Undervalued Biotechnology Industry Stocks by The Globe and Mail
- Opportunities for investment and collaboration with Rakovina Therapeutics
ABOUT RAKOVINA THERAPEUTICS
At Rakovina Therapeutics (TSX.V: RKV), our mission has always been about improving the lives of those battling cancer. Now, with a robust Artificial Intelligence (AI) platform on our side, we're moving into a new era of research speed and accuracy.
Using our Deep DockingTM platform powered by advanced AI algorithms, we can quickly analyze billions of molecular structures to evaluate their potential as targeted cancer drugs. We then validate their activity using our established R&D infrastructure. This approach is innovative to developing new therapies that target DNA-damage response-related vulnerabilities that are common in many types of cancer.
At Rakovina Therapeutics, we're wholly committed to pushing the boundaries of discovery and research using the latest technological advances to save lives worldwide.
MEET THE SPEAKERS
Meet some the incredibly experienced team of Rakovina Therapeutics (TSXV: RKV)
Jeffrey Bacha, BSc, MBA - Executive Chairman/Director
- 25 years as a member of the executive leadership team for multiple companies
- Founder and chief executive officer of Edison Oncology Holding Corp.
- Co-founded Kintara Therapeutics (NASDAQ: KTRA)
- Served as president and founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals and Vice President, Corporate Development at Inflazyme Corp.
- Member of the National Brain Tumor Society Research Roundtable and the Board of the Leukemia Lymphoma Society of Canada
- Currently serves as a consultant to DelMar Pharmaceuticals and Valent Technologies LLC, and as a member of the Board of Directors of Sernova Corp. (TSX-V: SVA)
Mads Daugaard, PhD - President & Chief Scientific Officer
- World Leader in translational cancer research
- Expertise in DNA-damage response mechanisms and therapeutics targeting DNA integrity
- Senior Research Scientist at Vancouver Prostate Centre
- Associate Professor at University of British Columbia, Department of Urologic Sciences
- Published in top-tier journals including Nature Structural & Molecular Biology, Nature Communications, Cancer Cell, and Molecular Cell
- Co-founder of VAR2 Pharmaceuticals (2012) and VarCT Diagnostics (2017)
- Former CSO of VAR2 Pharmaceuticals (2012-2016)
Artem Cherkasov, PhD - SAB/Senior AI & Medicinal Chemistry Advisor
- Professor at UBC's Department of Urologic Sciences and Senior Scientist at Vancouver Prostate Centre.
- Specializes in computer-aided drug discovery (CADD), structure-activity modeling, and new cancer therapeutics.
- Co-authored 200+ research papers, filed 80+ patents, and licensed 6 drug candidates to major companies.
- Androgen receptor inhibitor licensed by Roche in 2015 for a record $142M.
- Led a successful $24M grant application to create a comprehensive drug discovery infrastructure at UBC.
- Utilized AI-based platform, Deep Docking, to identify potential COVID-19 treatments, sharing findings with the scientific community.
- Holds multiple research grants from prestigious organizations like NSERC, CIHR, and NIH.
- Appointed Tier 1 Canada Research Chair in Precision Cancer Drug Design in January 2022.
